TIME highlights GARDP’s central role in advancing zoliflodacin, a first-in-class treatment for uncomplicated urogenital gonorrhoea approved by the US FDA in December 2025.
🔗 GARDP statement: gardp.org/dr-manica-ba...
#GlobalHealth #AntimicrobialResistance